Clinical TrialsSearch results
Number of results: 610
Other
- A phase 2 multicenter study evaluating the safety and efficacy of Nilotinib in patients with Imatinib-resistant/intolerant Ph+CML in chronic phase
- Chronic myelogenous leukemia
- Shimousa Hematology Study Group
- 2009-06-01
Other
- A phase 2 neoadjuvant chemotherapy of Irinotecan (CPT-11) plus Nedaplatin (NDP) for stage 1b2 or 2 cervical cancer of the uterine cervix
- stage 1b2/2 cervical cancer
- Japanese Gynecologic Oncology Group
- 2006-12-21
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A phase 3 study of gemcitabine and S-1 compared with gemcitabine monotherapy in patients with unresectable advanced pancreatic cancer.
- pancreatic cancer
- Chiba Cancer Center
- 2009-07-24
Completed
- A Phase I/II clinical trial of Carbon-ion radiotherapy for patients with immune checkpoint inhibitor resistant metastatic renal cell carcinoma
- Renal cell carcinoma
- Kasuya Goro
- 2019-10-07
Other
- A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI)
- Metastatic colorectal cancer isolated in the liver
- Japan Clinical Oncology Group(JCOG)
- 2005-08-08
No Longer Recruiting
- A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion
- hepatocellular carcinoma
- Ogasawara Sadahisa
- 2021-04-22